<DOC>
	<DOCNO>NCT02487849</DOCNO>
	<brief_summary>The combination optimal cytoreductive operation ( accord Desktop II criterion ) , HIPEC Carboplatin 800 mg/m² KOF ( Körperoberfläche ) follow platinum-based systemic chemotherapy execute In patient platinum-sensitive recurrence ovarian carcinoma . Condition HIPEC attainment optimal cytoreduction ( R0 ) expert judgement complication-free prolongation narcosis finishing surgery . HIPEC administer additionally standard therapy . If HIPEC execute number systemic give platinum-based chemotherapy decrease one cycle . This regime investigate term safety performance , quality life patient consequence follow systemic chemotherapy .</brief_summary>
	<brief_title>HIPEC After Secondary Cytoreductive Operation Patients With Platinum-sensitive Recurrence Ovarian Carcinoma</brief_title>
	<detailed_description>In occurence platinum-sensitive recurrence EOC survival prolong recurrence-operation , macroscopical tumor-free status ( optimal cytoreductive operation ) reach combination platinum-based standard-chemotherapy . Several study show combination optimal cytoreductive operation HIPEC secure method treatment . In comparison operation standard-chemotherapy significant positive influence survival rate . A hyperthermal intraperitoneal chemotherapy Carboplatin possible without severe side-effects . The combination optimal cytoreductive operation ( accord Desktop II criterion ) , HIPEC Carboplatin follow platinum-based systemic chemotherapy carry patient platinum-sensitive recurrence . Condition apply HIPEC reach optimal cytoreduction ( &lt; 0.5 cm visible tumour rest end operation ) accord expert opinion complicatin-free prolongation narcosis finish operative intervention . HIPEC carry additionally standard therapy . If carry , amount systemically administer patinum-based chemotherapy reduce one cycle . This regime test safety performance , quality life patient , consequence follow systemic chemotherapy .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>≥18 year Signed informed consent Patients platinumsensitive recurrence 1248 month platinumbased firstlinechemotherapy histological save epithelial ovarian carcinoma , primary peritoneal carcinoma tube carcinoma plan cytoreductive operation The following histological type include : serous , endometrioide , clear cell undifferentiated carcinoma . Mixed epithelial carcinoma , malignant Brenner Tumour No precede recurrence chemotherapy Preceding hormontherapy admit . Concomitant antineoplastic antihormonetherapy ( Tamoxifen , Aromataseinhibitoren etc . ) admit . Low dose ( physiological ) hormonereplacementtherapie ( HRT ) administer Patients maintenance therapy ( e.g . Bevacizumab ) permit , assume recurrence diagnose 12 month primary cytotoxic chemotherapy ( also maintenancetherapy chemotherapy ) last administration maintenancetherapy happen min . 21 day first study protocol intervention Resectability R0 probably , fix Desktop IIcriteria : Cytoreductive operation firstdiagnosis carcinoma R0 Ascites &lt; 500 ml ECOG 0 R0 status ( ≤0,5 cm tumour rest ) end secondary cytoreductive operation Eligibility Standard systemic platinumbased combination chemotherapy sec . cytoreductive operation without HIPEC ( investigator decision ) Bone marrow function : Haemoglobine ≥8.5 g/dL , Absol . neutrophile Granulocytes ( ANC ) ≥1.000/mm3 , Thrombocytes ≥ 100.000/mm3 Renal function : Serum Creatinin ≤1,5 time ULN , calculate Creatininclearance ( GFR ) ≥60ml/min Liver function : Bilirubin ≤1,5 x ALT , AST ≤3 x ULN Adequate coagulation parameter : INRvalue ≤1,5 , aPTT ≤1,5 x ULN For patient fullydosed/therapeutic Warfarin Phenprocoumontherapy INR 23 aPTT &lt; 1,2 x ULN Neurol . Function : peripheral Neuropathy ≤Grade 2 ( CTCAE v4.03 criterion ) In woman childbearing potential availability neg . serum pregnancy test 2 week plan sec . cytored . operation + effective contraception study period guarantee No sign inform consent Tumours low malignant potential ( Borderlinecarzinomas ) Patients precede radiotherapy abdomen pelvis Patients precede endometrial carcinoma exclude , except : Stage IA [ low differentiate subtype ( serouspapillary , clear cellular , FIGO grade 3 ) ] With exception nonmelanoma skin cancer specific malignancy note , subject invasive malignancy , evidence cancer present within last 3 year whose previous cancer treatment contraindicate protocol therapy , exclude Known acute hepatitis acute infectious disease need intravenous antibiosis immunodeficiency Active coronaryarterial disease : Myocardinfarct instable Angina pectoris within 6 month study inclusion : coronary artery disease anamnesis include , assume normal stresselectrocardiogram find within 30 day study inclusion Cardiac insufficiency NYHA ≥2 classif . New York Heart Association Hypertension ≥140/90 mm Hg Poorly control cardiac arrythmia despite medication ( patient frequenceycontrolled atrial fibrillation participate ) Peripheral vascular disease ≥grade 3 ( e.g . symptomatic affecting activity everydaylife , intervention revision necessary ) Renal insufficiency Serumcreatininvalues ≥1,5 time ULN GFR &lt; 60ml/min Cerebrovascular disease anamnesis Patients another severe medical problemindependent cancerwhich exclude study participation Known allergies Carboplatin Cisplatin extend intraperitoneal adhesion time secondary cytoreductive operation , make administration intraperitioneal chemotherapy impossible Life expectancy &lt; 12 week</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>